Mallinckrodt PLC (MNK) vs. The Competition Financial Analysis
Mallinckrodt PLC (NYSE: MNK) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Mallinckrodt PLC to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.
Earnings and Valuation
This table compares Mallinckrodt PLC and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mallinckrodt PLC||$3.27 billion||$666.60 million||7.91|
|Mallinckrodt PLC Competitors||$2.40 billion||$905.93 million||-0.42|
Mallinckrodt PLC has higher revenue, but lower earnings than its competitors. Mallinckrodt PLC is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
97.4% of Mallinckrodt PLC shares are owned by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 0.8% of Mallinckrodt PLC shares are owned by insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for Mallinckrodt PLC and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mallinckrodt PLC Competitors||66||309||957||27||2.70|
Mallinckrodt PLC currently has a consensus price target of $59.97, indicating a potential upside of 84.98%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 19.97%. Given Mallinckrodt PLC’s stronger consensus rating and higher possible upside, analysts plainly believe Mallinckrodt PLC is more favorable than its competitors.
This table compares Mallinckrodt PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mallinckrodt PLC Competitors||-607.55%||-56.08%||-29.50%|
Volatility & Risk
Mallinckrodt PLC has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Mallinckrodt PLC’s competitors have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.
Mallinckrodt PLC beats its competitors on 10 of the 13 factors compared.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.